Featured Content

Bendamustine-triplet in Front-line Multiple Myeloma

The combination of bendamustine, bortezomib, and dexamethasone was reported to be effective in achieving overall response rates in myeloma.

Is There a Link Between Familial Autoimmunity and Lymphoma?

Research is needed to identify the potentially overlapping molecular pathways involved in autoimmunity and B-cell neoplasms.

ASCO Advance of the Year: Immunotherapy 2.0

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."

Multiple Myeloma: Survival Hinges on Treatment Facility Volume

Patients who are treated for multiple myeloma at high-volume cancer centers have better survival outcomes than those receiving care at low-volume facilities.

Selinexor for Relapsed/Refractory Multiple Myeloma

Selinexor represents a much-needed therapeutic addition to the available agents for the treatment of heavily pre-treated patients with few options.

Video Series

Multiple Myeloma Resources

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters